Disease · MONDO_0000430

mature T-cell and NK-cell non-Hodgkin lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mature T-cell and NK-cell non-Hodgkin lymphoma. Diseases, record MONDO_0000430. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000430

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mature T-cell and NK-cell non-Hodgkin lymphoma; Open Targets
Open Targets ID: MONDO_0000430; Open Targets
Other names: PTCL, mature T-and NK-cell lymphoma, mature T-cell and NK-cell lymphoma, mature T-cell and NK-cell non-Hodgkin's lymphoma, mature T-cell lymphoma, mature T-cell non-Hodgkin's lymphoma, peripheral T-cell lymphoma; Open Targets
Disease Ontology: DOID:0050743; Disease Ontology
Disease Ontology: DOID:0050749; Disease Ontology
MeSH: D016411; MeSH
NCI Thesaurus: C3468; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 139 drugs, from PMDA and TTD; Open Targets

Drugs139

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ROMIDEPSIN	CHEMBL343448	Protein	Approval	PMDA	26	24	24	Drugs and targets
PRALATREXATE	CHEMBL1201746	Small molecule	Approval	PMDA and TTD	15	13	13	Drugs and targets
DENILEUKIN DIFTITOX	CHEMBL1201550	Protein	Approval	PMDA	2	1	1	Drugs and targets
DARINAPARSIN	CHEMBL3247378	Small molecule	Approval	PMDA	2	0	0	Drugs and targets
FORODESINE HYDROCHLORIDE	CHEMBL550755	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	45	45	42	Drugs and targets
TUCIDINOSTAT	CHEMBL3621988	Small molecule	Phase 3	ClinicalTrials.gov	39	39	39	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	35	35	31	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	33	33	30	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	28	28	25	Drugs and targets

1 to 10 of 139

See all 139 drugs

Targets179

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	8	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
HDAC1	Histone deacetylase	5	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	5	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	5	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	5	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/10013	Drugs and targets
JAK1	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	5	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
HDAC10	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC4	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/9759	Drugs and targets

1 to 10 of 179

See all 179 targets

Trials224

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01777152	ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas	Phase 3	452	2019-07-30	Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma	BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT01482962	Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma	Phase 3	271	2018-07-31	Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma	ALISERTIB, GEMCITABINE, PRALATREXATE, ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT04105010	Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)	Phase 1/2	171	2025-04-04	Relapsed or Refractory Peripheral T Cell Lymphoma	GOLIDOCITINIB	Its record names the disease	ClinicalTrials.gov
NCT04703192	Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)	Phase 2	155	2024-07-22	Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma	VALEMETOSTAT TOSYLATE	Its record names the disease	ClinicalTrials.gov
NCT02581631	An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas	Phase 1/2	145	2023-03-07	Non-Hodgkin's Disease	BRENTUXIMAB VEDOTIN, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00007345	Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma	Phase 2	131	2016-02-12	Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma	ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT01716806	A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	Phase 2	131	2024-06-11	Hodgkin Disease, Peripheral T Cell Lymphoma	BENDAMUSTINE, BRENTUXIMAB VEDOTIN, DACARBAZINE, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT04101331	Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides	Phase 2	108	2023-06-05	Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides	ACIMTAMIG	Its record names the disease	ClinicalTrials.gov
NCT05011058	An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas	Phase 2	102	2025-07-28	Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder	NANATINOSTAT, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT04213209	Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"		95	2024-09-27	Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 224

See all 224 trials

Comparisons in its trials32

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
A+CHP vs CHOP: Objective Response Rate (ORR) Per IRF at End of Treatment	188 of 226	163 of 226	452	NCT01777152	Trial comparisons
A+CHP vs CHOP: Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)	153 of 226	126 of 226	452	NCT01777152	Trial comparisons
Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) vs Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma: deaths from any cause	52 of 133	16 of 22	155	NCT04703192	Trial comparisons
Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) vs Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma: serious adverse events	53 of 133	15 of 22	155	NCT04703192	Trial comparisons
Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): deaths from any cause	6 of 47	5 of 84	131	NCT00007345	Trial comparisons
Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): Number of Participants With Adverse Events	47 of 47	84 of 84	131	NCT00007345	Trial comparisons
Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): serious adverse events	20 of 47	38 of 84	131	NCT00007345	Trial comparisons
CD30 <1% [Local Laboratory Assessment] vs CD30 1% to <10% [Local Laboratory Assessment]: deaths from any cause	11 of 34	13 of 48	82	NCT04569032	Trial comparisons
CD30 <1% [Local Laboratory Assessment] vs CD30 1% to <10% [Local Laboratory Assessment]: serious adverse events	15 of 34	16 of 48	82	NCT04569032	Trial comparisons
Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): deaths from any cause	31 of 47	11 of 13	60	NCT01431209	Trial comparisons

1 to 10 of 32

See all 32 comparisons in its trials

Papers from its trials112

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31123029	RESULT	1	PubMed
31029646	RESULT	2	PubMed
30694529	RESULT	1	PubMed
29720488	RESULT	1	PubMed
29293620	RESULT	1	PubMed
29143824	RESULT	1	PubMed
29072976	RESULT	1	PubMed
28974506	RESULT	1	PubMed
28600132	RESULT	1	PubMed
28570279	RESULT	1	PubMed

1 to 10 of 112

See all 112 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000430

GET https://conductscience.org/api/diseases/v1/MONDO_0000430/drugs?page=2

API reference For AI assistants